Abstract Details
| David Uzenot, MD (Service de Neurologie et de Pathologie Neurom) | No disclosure on file |
| No disclosure on file | |
| Annie Verschueren (Genzyme) | No disclosure on file |
| Joshuae Gallardo, MD (G2 Neuroscience Associates PLLC) | No disclosure on file |
| No disclosure on file | |
| Shahram Attarian, MD, PhD (CHU La Timone Aix Marseille University) | Prof. Attarian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI, Pfizer LFB, Alnylam Biogen Argenx, UCB Alexion, Astrazenica, Amicus, Janssen, Novartis, Roche. Prof. Attarian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SANOFI, Biogen,Alnylam, Argenx, USB, Alexion Astrazenica, Janssen, Roche, Amgen. The institution of Prof. Attarian has received research support from National Institut of Health . |
| Jean P. Azulay, MD | Dr. Azulay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for abbvie. Dr. Azulay has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. |
| Jean Pouget, MD, PhD (CHU La Timone) | No disclosure on file |